Note that with p53 or other components of this cancer prevention system mutated such that L1 signaling does not halt growth, L1 activation might become a clinical detriment by permitting faster cancer evolution through L1 mediated insertional mutagenesis. The gene discussed is TP53; the disease is cancer.